Psychotic Disorders - Estonia | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$4.22m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.83%, resulting in a market volume of US$4.40m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$362.20 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Estonia is experiencing steady growth due to several factors. Customer preferences for effective and accessible treatment options, along with increasing awareness and diagnosis rates, are driving the demand for products in this market. Additionally, local special circumstances and underlying macroeconomic factors contribute to the development of the Psychotic Disorders market in Estonia.

Customer preferences: Customers in Estonia prefer treatment options that are effective and accessible. They seek medications that can effectively manage the symptoms of psychotic disorders and improve their overall quality of life. Additionally, customers value treatments that have minimal side effects and are easy to administer. As a result, pharmaceutical companies are focusing on developing innovative drugs that meet these customer preferences.

Trends in the market: One of the key trends in the Psychotic Disorders market in Estonia is the increasing awareness and diagnosis rates. With growing public awareness about mental health and the availability of better diagnostic tools, more individuals are being diagnosed with psychotic disorders. This trend is driving the demand for medications and other treatment options in the market.Another trend in the market is the development of new and improved medications. Pharmaceutical companies are investing in research and development to create innovative drugs that can effectively manage the symptoms of psychotic disorders. These new medications aim to provide better outcomes for patients, with fewer side effects and improved tolerability.

Local special circumstances: One of the local special circumstances that impact the Psychotic Disorders market in Estonia is the availability of healthcare services. Estonia has a well-developed healthcare system with a strong emphasis on mental health. The government has implemented policies to improve access to mental health services and promote early intervention. This focus on mental health has created a favorable environment for the development and growth of the Psychotic Disorders market in Estonia.

Underlying macroeconomic factors: The underlying macroeconomic factors in Estonia also contribute to the development of the Psychotic Disorders market. The country has experienced stable economic growth in recent years, which has led to an increase in healthcare spending. The government has allocated resources to improve mental health services, including the availability of medications for psychotic disorders. This favorable economic environment supports the growth of the market by ensuring the availability of funding for research, development, and healthcare infrastructure.In conclusion, the Psychotic Disorders market in Estonia is developing due to customer preferences for effective and accessible treatment options, increasing awareness and diagnosis rates, local special circumstances such as the availability of healthcare services, and underlying macroeconomic factors including stable economic growth and government support. These factors contribute to the growth and expansion of the market, providing opportunities for pharmaceutical companies and healthcare providers to meet the needs of individuals with psychotic disorders in Estonia.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.